LTFS
TVRD

Ladenburg Thalmann Financial Services’s Tvardi Therapeutics TVRD Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$444K Sell
765
-338
-31% -$237K ﹤0.01% 1910
2019
Q3 		$726K Sell
1,103
-98
-8% -$81.5K 0.01% 1469
2019
Q2 		$931K Sell
1,201
-25
-2% -$17.6K 0.01% 1279
2019
Q1 		$865K Buy
1,226
+170
+16% +$102K 0.01% 1285
2018
Q4 		$494K Buy
1,056
+752
+247% +$485K ﹤0.01% 1537
2018
Q3 		$262K Buy
304
+202
+198% +$146K ﹤0.01% 2095
2018
Q2 		$45K Hold
102
– – ﹤0.01% 3330
2018
Q1 		$45K Buy
102
+10
+11% +$4.85K ﹤0.01% 3330
2017
Q4 		$41K Buy
92
+4
+5% +$1.82K ﹤0.01% 3362
2017
Q3 		$44K Buy
88
+22
+33% +$11K ﹤0.01% 3177
2017
Q2 		$36K Sell
66
-79
-54% -$50.1K ﹤0.01% 3245
2017
Q1 		$96K Buy
145
+133
+1,108% +$71K ﹤0.01% 2433
2016
Q4 		$4K Buy
12
+4
+50% +$1.28K ﹤0.01% 4343
2016
Q3 		$3K Hold
8
– – ﹤0.01% 4386
2016
Q2 		$1K Buy
+8
New +$1.74K ﹤0.01% 4627

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Ladenburg Thalmann Financial Services's TVRD Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Tvardi Therapeutics (TVRD) stake by 31% in Q4 2019, selling an estimated $237K and leaving 765 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

Ladenburg Thalmann Financial Services first reported a position in TVRD in Q2 2016 and has held it in 15 quarters since. The position peaked at $931K in Q2 2019. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 765 shares of Tvardi Therapeutics worth $444K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 338 Tvardi Therapeutics shares in Q4 2019, an estimated $237K.
  • Tvardi Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1910 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Tvardi Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Ladenburg Thalmann Financial Services's Tvardi Therapeutics position peaked at $931K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.